Kevin Mcculloch Sells $312K of Xeris Biopharma Holdings Inc (XERS) — SEC Form 4, Nov 06, 2026
Open-Market Net Sale · SEC Form 4
−$312,215
10b5-1 Plan
Equity position changed by -1.6%
Equity Position
1.58M sh
1,609,208 → 1,584,208
Equity Change
-1.6%
shares held after vs before
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Kevin Mcculloch CIK 0002031695 |
COO
|
Kevin Mcculloch at Xeris Biopharma Holdings Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$1,946,882
More from this insider at Xeris Biopharma Holdings Inc
| 2026-11-04 | Sell | -$153,488 | View |
| 2026-10-02 | Sell | -$141,120 | View |
| 2026-09-29 | Sell | -$250,000 | View |
| 2026-09-01 | Sell | -$127,308 | View |
| 2026-08-21 | - | — | View |
Non-Derivative Securities Transactions
Non-Derivative Holdings
| Title | Shares Held | Ownership |
|---|---|---|
| Common StockF3 | 25,000 | Indirect By Spouse |
Footnotes (3)
- F1
- The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. Show more
- F2
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.380 to $12.510, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Show more
- F3
- The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Show more
Remarks
President and Chief Operating Officer
Show moreRelated filings at Xeris Biopharma Holdings Inc
Institutional Holders
13F holders · Jun 30, 2026
240
institutional managers reporting a position
Largest by reported value
- Black Rock, Inc. $115M
- D. E. Shaw & Co., Inc. $61.8M
- Vanguard Capital Management Llc $58.1M
Other insiders at Xeris Biopharma Holdings Inc
-
Steven Pieper -$51.2K
-
Beth Hecht -$256K
-
Steven Pieper -$47K
-
Beth Hecht -$157K
GET /v1/forms/4/0001867096-26-000119
API docs
View Original SEC Filing